These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17685736)

  • 1. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
    Kocsis JH; Thase ME; Trivedi MH; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT; Keller MB
    J Clin Psychiatry; 2007 Jul; 68(7):1014-23. PubMed ID: 17685736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
    J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    Kornstein SG; Pedersen RD; Holland PJ; Nemeroff CB; Rothschild AJ; Thase ME; Trivedi MH; Ninan PT; Keller MB
    J Clin Psychiatry; 2014 Jan; 75(1):62-8. PubMed ID: 24345717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
    Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
    J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study.
    Kornstein SG
    CNS Spectr; 2006 Dec; 11(12 Suppl 15):28-34. PubMed ID: 17146416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
    Rothschild AJ; Dunlop BW; Dunner DL; Friedman ES; Gelenberg A; Holland P; Kocsis JH; Kornstein SG; Shelton R; Trivedi MH; Zajecka JM; Goldstein C; Thase ME; Pedersen R; Keller MB
    Psychopharmacol Bull; 2009; 42(3):5-20. PubMed ID: 19752838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Dunlop BW; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen R; Yan B; Ahmed S; Schmidt M; Ninan PT
    Biol Psychiatry; 2007 Dec; 62(12):1371-9. PubMed ID: 17825800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release.
    Ferguson JM; Khan A; Mangano R; Entsuah R; Tzanis E
    J Clin Psychiatry; 2007 Jan; 68(1):58-68. PubMed ID: 17284131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine versus placebo in the preventive treatment of recurrent major depression.
    Montgomery SA; Entsuah R; Hackett D; Kunz NR; Rudolph RL;
    J Clin Psychiatry; 2004 Mar; 65(3):328-36. PubMed ID: 15096071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.
    Davidson J; Baldwin D; Stein DJ; Kuper E; Benattia I; Ahmed S; Pedersen R; Musgnung J
    Arch Gen Psychiatry; 2006 Oct; 63(10):1158-65. PubMed ID: 17015818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity.
    Sauer H; Huppertz-Helmhold S; Dierkes W
    Pharmacopsychiatry; 2003 Sep; 36(5):169-75. PubMed ID: 14571350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
    Liebowitz MR; Gelenberg AJ; Munjack D
    Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder.
    Liebowitz MR; Asnis G; Mangano R; Tzanis E
    J Clin Psychiatry; 2009 Apr; 70(4):550-61. PubMed ID: 19358784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo.
    Rothbaum BO; Davidson JR; Stein DJ; Pedersen R; Musgnung J; Tian XW; Ahmed S; Baldwin DS
    J Clin Psychiatry; 2008 Oct; 69(10):1529-39. PubMed ID: 19192435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A; Roose S
    Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.